Last reviewed · How we verify
Anti-Parkinson medication
This drug works by increasing dopamine levels in the brain to alleviate Parkinson's symptoms.
This drug works by increasing dopamine levels in the brain to alleviate Parkinson's symptoms. Used for Parkinson's disease, Flu-like syndrome.
At a glance
| Generic name | Anti-Parkinson medication |
|---|---|
| Also known as | Carbidopa/levodopa, pramipexole, ropinirole, amantadine, tolcapone |
| Sponsor | Beth Israel Deaconess Medical Center |
| Drug class | Dopamine agonist |
| Target | Dopamine receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
It does this by inhibiting the enzyme responsible for breaking down dopamine, allowing more dopamine to be available for the brain's use. This leads to improved motor function and reduced symptoms of Parkinson's disease.
Approved indications
- Parkinson's disease
- Flu-like syndrome
Common side effects
- Nausea
- Dizziness
- Headache
- Fatigue
- Dyskinesia
Key clinical trials
- Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease
- Role of Pentoxifylline and Celecoxib in Parkinsonism (PHASE2)
- Gait Analysis in Neurological Disease
- Investigating the Neural Signature of Freezing of Gait in Parkinson's Disease
- Neuroprotective Effects of Long-term TaVNS in Early Parkinson's Disease Patients (NA)
- An Open-label Study on the Clinical Efficacy of tDCS Intervention in PD (NA)
- Effects of a Periodic Repetitive Transcranial Magenetic Stimulation in Parkinson Disease (NA)
- Safety and Efficacy of Botulinum Toxin A for Treatment of Overactive Bladder in Parkinson's Disease (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-Parkinson medication CI brief — competitive landscape report
- Anti-Parkinson medication updates RSS · CI watch RSS
- Beth Israel Deaconess Medical Center portfolio CI